Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Acquired by Janus Henderson Group PLC

Janus Henderson Group PLC lifted its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 28.3% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 47,957 shares of the company’s stock after purchasing an additional 10,575 shares during the period. Janus Henderson Group PLC’s holdings in Intellia Therapeutics were worth $985,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. ARK Investment Management LLC boosted its position in Intellia Therapeutics by 5.7% in the 3rd quarter. ARK Investment Management LLC now owns 12,255,440 shares of the company’s stock valued at $251,849,000 after buying an additional 659,651 shares during the period. Federated Hermes Inc. boosted its holdings in Intellia Therapeutics by 19.2% in the second quarter. Federated Hermes Inc. now owns 2,300,889 shares of the company’s stock valued at $51,494,000 after purchasing an additional 371,189 shares during the period. BNP Paribas Financial Markets grew its stake in Intellia Therapeutics by 88.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 246,362 shares of the company’s stock worth $5,063,000 after purchasing an additional 115,351 shares in the last quarter. FMR LLC grew its stake in Intellia Therapeutics by 5.0% during the 3rd quarter. FMR LLC now owns 2,339,522 shares of the company’s stock worth $48,077,000 after purchasing an additional 111,104 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its position in Intellia Therapeutics by 8.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,324,561 shares of the company’s stock valued at $29,648,000 after purchasing an additional 98,865 shares in the last quarter. Institutional investors and hedge funds own 88.77% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on NTLA. The Goldman Sachs Group cut their target price on shares of Intellia Therapeutics from $31.00 to $20.00 and set a “neutral” rating on the stock in a research note on Friday, October 25th. StockNews.com raised shares of Intellia Therapeutics to a “sell” rating in a research report on Friday, November 8th. Wedbush reaffirmed a “neutral” rating and set a $14.00 price objective on shares of Intellia Therapeutics in a research report on Monday, November 18th. Robert W. Baird dropped their target price on Intellia Therapeutics from $24.00 to $18.00 and set a “neutral” rating on the stock in a report on Friday, October 25th. Finally, Barclays cut their price target on Intellia Therapeutics from $76.00 to $55.00 and set an “overweight” rating on the stock in a research note on Friday, November 8th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Intellia Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $54.94.

Intellia Therapeutics Price Performance

Shares of NASDAQ:NTLA opened at $12.90 on Friday. The stock has a market cap of $1.31 billion, a P/E ratio of -2.37 and a beta of 1.76. Intellia Therapeutics, Inc. has a 1-year low of $12.47 and a 1-year high of $34.87. The firm has a fifty day moving average price of $16.23 and a 200 day moving average price of $20.70.

Intellia Therapeutics (NASDAQ:NTLA) last announced its earnings results on Thursday, November 7th. The company reported ($1.34) earnings per share for the quarter, topping the consensus estimate of ($1.37) by $0.03. The business had revenue of $9.10 million for the quarter, compared to analyst estimates of $8.28 million. Intellia Therapeutics’s quarterly revenue was down 24.1% on a year-over-year basis. During the same quarter last year, the company posted ($1.38) EPS. Sell-side analysts expect that Intellia Therapeutics, Inc. will post -5.12 EPS for the current fiscal year.

Insider Buying and Selling at Intellia Therapeutics

In related news, CAO Michael P. Dube sold 2,012 shares of Intellia Therapeutics stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $19.01, for a total value of $38,248.12. Following the transaction, the chief accounting officer now directly owns 47,012 shares in the company, valued at $893,698.12. This trade represents a 4.10 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 3.20% of the company’s stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.